Another public biotech hops on the trial-win-to-public-offering train, netting a nine-figure raise

After unveiling Phase II data that, according to Rezolute, “exceeded expectations” with a drug for congenital hyperinsulinism, the Silicon Valley-based biotech is now raising a combined $130 million in a public offering and private placement to continue clinical trials.